Nabi initiated by Thomas Weisel at peer perform

Nabi Biopharmaceuticals coverage was initiated by Thomas Weisel Partners analyst Joe Slavinsky at a peer perform rating. Thomas Weisel believes that a European Union approval and positive phase III data for StaphVAX in the United States are broadly expected and already priced into the stock. Although longer term prospects are promising, the firm does not believe that the near-term risk/reward profile is compelling. Nabi shares Wednesday were up $0.20, or 1.51%, at $13.47 on volume of 643,349 shares versus the three-month running average of 712,692 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.